PL378064A1 - Pirymidyny i triazyny hamujące replikację wirusa HIV - Google Patents

Pirymidyny i triazyny hamujące replikację wirusa HIV

Info

Publication number
PL378064A1
PL378064A1 PL378064A PL37806404A PL378064A1 PL 378064 A1 PL378064 A1 PL 378064A1 PL 378064 A PL378064 A PL 378064A PL 37806404 A PL37806404 A PL 37806404A PL 378064 A1 PL378064 A1 PL 378064A1
Authority
PL
Poland
Prior art keywords
hiv replication
triazines
replication inhibiting
inhibiting pyrimidines
pyrimidines
Prior art date
Application number
PL378064A
Other languages
English (en)
Other versions
PL226954B1 (pl
Inventor
Jerome Emile Georges Guillemont
Elisabeth Therese Jeanne Pasquier
Jan Heeres
Kurt Hertogs
Eva Bettens
Paulus Joannes Lewi
Jonge Marc Rene De
Lucien Maria Henricus Koymans
Frederik Frans Desire Daeyaert
Hendrik Maarten Vinkers
Paul Adrian Jan Janssen
Original Assignee
Tibotec Pharmaceuticals Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharmaceuticals Ltd. filed Critical Tibotec Pharmaceuticals Ltd.
Publication of PL378064A1 publication Critical patent/PL378064A1/pl
Publication of PL226954B1 publication Critical patent/PL226954B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem wynalazku są inhibitory replikacji wirusa HIV o wzorze (I), ich N-tlenki, ich sole addycyjne dopuszczone do stosowania w farmacji, ich czwartorzędowe związki aminowe oraz ich stereochemiczne postacie izomeryczne, ich zastosowanie w medycynie, sposoby ich wytwarzania oraz zawierające je kompozycje farmaceutyczne.
PL378064A 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny PL226954B1 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03100411.2 2003-02-20
EP03100411 2003-02-20
US47501203P 2003-06-02 2003-06-02
US60/475,012 2003-06-02
PCT/EP2004/050175 WO2004074261A1 (en) 2003-02-20 2004-02-20 Hiv replication inhibiting pyrimidines and triazines

Publications (2)

Publication Number Publication Date
PL378064A1 true PL378064A1 (pl) 2006-02-20
PL226954B1 PL226954B1 (pl) 2017-10-31

Family

ID=32910137

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378136A PL227295B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV
PL378064A PL226954B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV, kompozycja farmaceutyczna iprodukt jazawierajacy oraz sposób wytwarzania pochodnej pirymidyny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378136A PL227295B1 (pl) 2003-02-20 2004-02-20 Pochodna pirymidyny hamujaca replikacje wirusa HIV

Country Status (27)

Country Link
US (2) US7585870B2 (pl)
EP (2) EP1597238B1 (pl)
JP (2) JP4586013B2 (pl)
KR (2) KR20050099994A (pl)
CN (2) CN100572364C (pl)
AP (1) AP2005003373A0 (pl)
AR (2) AR044499A1 (pl)
AT (2) ATE361915T1 (pl)
AU (2) AU2004213187B2 (pl)
BR (2) BRPI0407741B8 (pl)
CA (2) CA2516699C (pl)
CL (2) CL2004000306A1 (pl)
CY (1) CY1106788T1 (pl)
DE (2) DE602004006383T2 (pl)
DK (1) DK1597238T3 (pl)
EA (2) EA010423B1 (pl)
ES (1) ES2287734T3 (pl)
HR (2) HRP20050820A2 (pl)
IL (2) IL169596A (pl)
MX (2) MXPA05008866A (pl)
MY (1) MY138308A (pl)
NO (2) NO20054311L (pl)
NZ (2) NZ541601A (pl)
PL (2) PL227295B1 (pl)
PT (1) PT1597238E (pl)
TW (2) TW200500346A (pl)
WO (2) WO2004074261A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
PT1856135E (pt) 2005-01-19 2010-02-26 Rigel Pharmaceuticals Inc Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2007098507A2 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US8318736B2 (en) * 2006-12-29 2012-11-27 Janssen R&D Ireland HIV inhibiting 5,6-substituted pyrimidines
KR20090094073A (ko) * 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
ES2645689T5 (en) 2008-05-21 2025-06-24 Takeda Pharmaceuticals Co Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
TW201008933A (en) * 2008-08-29 2010-03-01 Hutchison Medipharma Entpr Ltd Pyrimidine compounds
NZ591366A (en) 2008-09-11 2012-05-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
AR074210A1 (es) 2008-11-24 2010-12-29 Boehringer Ingelheim Int Derivados de pirimidina como inhibidores de ptk2-quinasa
MY151246A (en) 2009-03-11 2014-04-30 Pfizer Benzofuranyl derivatives
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012135641A2 (en) 2011-03-30 2012-10-04 H. Lee Moffitt Cancer Center And Research Institute Aurora kinase inhibitors and methods of making and using thereof
BR112013027734A2 (pt) 2011-05-04 2017-08-08 Ariad Pharma Inc compostos para a inibição de proliferação celular em cânceres impulsionados pelo egfr, método e composição farmacêutica
GB201119358D0 (en) 2011-11-10 2011-12-21 Lewi Paulus J Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
GB201204756D0 (en) 2012-03-19 2012-05-02 Lewi Paulus J Triazines with suitable spacers for treatment and/or prevention of HIV infections
US20150166591A1 (en) 2012-05-05 2015-06-18 Ariad Pharmaceuticals, Inc. Methods and compositions for raf kinase mediated diseases
WO2014072419A1 (en) 2012-11-08 2014-05-15 Universiteit Antwerpen Novel anti-hiv compounds
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP3492462B1 (en) * 2016-07-26 2023-08-30 Shenzhen TargetRx, Inc. Amino pyrimidine compound for inhibiting protein tyrosine kinase activity
CN106749203B (zh) * 2016-11-28 2020-04-10 洛阳聚慧医药科技有限公司 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用
MX2021013662A (es) 2019-05-10 2022-03-11 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
SMT202300469T1 (it) 2019-05-10 2024-01-10 Deciphera Pharmaceuticals Llc Inibitori dell'autofagia a base di fenilamminopirimidinammidi, e metodi di loro utilizzo
CN114258318B (zh) 2019-06-17 2024-09-20 德西费拉制药有限责任公司 氨基嘧啶酰胺自噬抑制剂及其使用方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
AU725204B2 (en) 1995-11-23 2000-10-05 Janssen Pharmaceutica N.V. Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
CZ299380B6 (cs) * 1998-03-27 2008-07-09 Janssen Pharmaceutica N. V. Pyrimidinová sloucenina, použití této slouceniny pro prípravu léciva, farmaceutický prostredek tutoslouceninu obsahující, zpusob prípravy tohoto prostredku a uvedené slouceniny a kombinace a produktuvedenou slouceninu obsahující
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
EE05086B1 (et) 1998-11-10 2008-10-15 Janssen Pharmaceutica N.V. Primidiini derivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod, kombinatsioon ning saadus
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
TR200102969T2 (tr) 1999-04-15 2002-08-21 Bristol-Myers Squibb Company Siklik protein tirozin kinaz önleyicileri.
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EA005423B1 (ru) * 1999-09-24 2005-02-24 Янссен Фармацевтика Н.В. Противовирусные композиции
MXPA02003436A (es) * 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
WO2001085700A2 (en) 2000-05-08 2001-11-15 Janssen Pharmaceutica N.V. Hiv replication inhibiting pyrimidines and triazines
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003244463A1 (en) * 2002-02-05 2003-09-02 Yamanouchi Pharmaceutical Co., Ltd. 2,4,6-triamino-1,3,5-triazine derivative
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
ATE530530T1 (de) * 2002-06-28 2011-11-15 Astellas Pharma Inc Diaminopyrimidincarbonsäureamidderivat
DK1534286T3 (da) * 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
CL2004000306A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.

Also Published As

Publication number Publication date
MY138308A (en) 2009-05-29
CA2516589A1 (en) 2004-09-02
TW200500346A (en) 2005-01-01
BRPI0407732A (pt) 2006-02-14
JP4586013B2 (ja) 2010-11-24
CN1751031A (zh) 2006-03-22
DE602004032321D1 (de) 2011-06-01
NZ542428A (en) 2007-11-30
CA2516589C (en) 2012-04-17
DK1597238T3 (da) 2007-09-10
CN1751030A (zh) 2006-03-22
NO20054312D0 (no) 2005-09-19
TW200510339A (en) 2005-03-16
AR044499A1 (es) 2005-09-14
BRPI0407741A (pt) 2006-02-14
AR044500A1 (es) 2005-09-14
EP1597238B1 (en) 2007-05-09
CL2004000306A1 (es) 2005-04-08
PL227295B1 (pl) 2017-11-30
JP2006518356A (ja) 2006-08-10
EP1603887B1 (en) 2011-04-20
IL169647A (en) 2013-05-30
MXPA05008867A (es) 2005-10-05
EP1603887A1 (en) 2005-12-14
NO20054311L (no) 2005-10-27
AU2004213186A1 (en) 2004-09-02
KR20050099994A (ko) 2005-10-17
PT1597238E (pt) 2007-08-08
WO2004074262A1 (en) 2004-09-02
PL378136A1 (pl) 2006-03-06
AU2004213186B2 (en) 2009-10-01
PL226954B1 (pl) 2017-10-31
AU2004213187A1 (en) 2004-09-02
US20060142571A1 (en) 2006-06-29
JP4586014B2 (ja) 2010-11-24
EP1597238A1 (en) 2005-11-23
EA200501326A1 (ru) 2006-02-24
KR20050094896A (ko) 2005-09-28
EA200501327A1 (ru) 2006-02-24
NO20054312L (no) 2005-11-16
ATE506353T1 (de) 2011-05-15
JP2006518357A (ja) 2006-08-10
EA010423B1 (ru) 2008-08-29
HRP20050821A2 (en) 2006-11-30
US7585870B2 (en) 2009-09-08
BRPI0407741B8 (pt) 2021-05-25
DE602004006383T2 (de) 2008-01-10
WO2004074261A1 (en) 2004-09-02
NO20054311D0 (no) 2005-09-19
IL169647A0 (en) 2007-07-04
EA011256B1 (ru) 2009-02-27
US20060194804A1 (en) 2006-08-31
NZ541601A (en) 2007-09-28
US7442705B2 (en) 2008-10-28
CN100572364C (zh) 2009-12-23
CN1751031B (zh) 2010-07-21
CA2516699C (en) 2011-07-12
MXPA05008866A (es) 2005-10-05
ES2287734T3 (es) 2007-12-16
CY1106788T1 (el) 2012-05-23
ATE361915T1 (de) 2007-06-15
AU2004213187B2 (en) 2009-11-05
CA2516699A1 (en) 2004-09-02
BRPI0407741B1 (pt) 2018-05-29
CL2004000303A1 (es) 2005-04-08
HRP20050820A2 (en) 2006-11-30
AP2005003373A0 (en) 2005-09-30
DE602004006383D1 (de) 2007-06-21
IL169596A (en) 2017-02-28
IL169596A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
PL378064A1 (pl) Pirymidyny i triazyny hamujące replikację wirusa HIV
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
SE0202463D0 (sv) Novel compounds
PL378107A1 (pl) 1,2,4-triazyny hamujące HIV
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
NO20085087L (no) Nye heterocykliske forbindelser
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
BRPI0606313A2 (pt) derivados de 4-(1h-indol-3-il)-pirimidin-2-ilamina, processo para sua preparação e seu uso em terapia
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
MEP25908A (bs) Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitor kinaze
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
EA201070167A1 (ru) Замещенные производные индазола, активные как ингибиторы киназы
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
BR0316950A (pt) Derivados de indazol como antagonistas de crf
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
GB0308201D0 (en) Novel compounds
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
RS51435B (en) 2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE INHIBITING HIV